Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

An assessment of bioavailability of acrylate based pH-sensitive complexes of lovastatin.

Mehmood HQ, Faran SA, Chaudhry MA, Khalid SH, Khan IU, Hassan W, Ashfaq R, Asghar S.

Pak J Pharm Sci. 2019 May;32(3 (Supplementary)):1129-1136.

PMID:
31326870
2.

An assessment of bioavailability of acrylate based pH-sensitive complexes of lovastatin.

Mehmood HQ, Faran SA, Chaudhry MA, Khalid SH, Khan IU, Hassan W, Ashfaq R, Asghar S.

Pak J Pharm Sci. 2019 May;32(3 (Supplementary)):1129-1136.

PMID:
31303581
3.

Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology: A Multicenter Blinded Randomized Noninferiority Study of 1992 Cases (Pivotal Study).

Mukhopadhyay S, Feldman MD, Abels E, Ashfaq R, Beltaifa S, Cacciabeve NG, Cathro HP, Cheng L, Cooper K, Dickey GE, Gill RM, Heaton RP Jr, Kerstens R, Lindberg GM, Malhotra RK, Mandell JW, Manlucu ED, Mills AM, Mills SE, Moskaluk CA, Nelis M, Patil DT, Przybycin CG, Reynolds JP, Rubin BP, Saboorian MH, Salicru M, Samols MA, Sturgis CD, Turner KO, Wick MR, Yoon JY, Zhao P, Taylor CR.

Am J Surg Pathol. 2018 Jan;42(1):39-52. doi: 10.1097/PAS.0000000000000948.

4.

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS.

Lancet Oncol. 2017 Jun;18(6):779-791. doi: 10.1016/S1470-2045(17)30279-6. Epub 2017 Apr 21.

5.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

6.

Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept.

Neuzillet Y, Mertens L, Shariat S, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, Lotan Y, Van der Kwast T, Van Rhijn B.

Prog Urol. 2014 Nov;24(13):806-7. doi: 10.1016/j.purol.2014.08.054. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461579
7.

Somatic alterations in juvenile polyps from BMPR1A and SMAD4 mutation carriers.

Blatter RH, Plasilova M, Wenzel F, Gokaslan ST, Terracciano L, Ashfaq R, Heinimann K.

Genes Chromosomes Cancer. 2015 Sep;54(9):575-82. doi: 10.1002/gcc.22270. Epub 2015 Jul 14.

PMID:
26171675
8.

Techniques for cytologic sampling of pancreatic and bile duct lesions: The Papanicolaou Society of Cytopathology Guidelines.

Brugge WR, De Witt J, Klapman JB, Ashfaq R, Shidham V, Chhieng D, Kwon R, Baloch Z, Zarka M, Staerkel G.

Cytojournal. 2014 Jun 2;11(Suppl 1):2. doi: 10.4103/1742-6413.133311. eCollection 2014.

9.

Molecular markers of carcinogenesis for risk stratification of individuals with colorectal polyps: a case-control study.

Gupta S, Sun H, Yi S, Storm J, Xiao G, Balasubramanian BA, Zhang S, Ashfaq R, Rockey DC.

Cancer Prev Res (Phila). 2014 Oct;7(10):1023-34. doi: 10.1158/1940-6207.CAPR-14-0140. Epub 2014 Aug 4.

10.

Techniques for cytologic sampling of pancreatic and bile duct lesions.

Brugge W, Dewitt J, Klapman JB, Ashfaq R, Shidham V, Chhieng D, Kwon R, Baloch Z, Zarka M, Staerkel G; Papanicolaou Society of Cytopathology.

Diagn Cytopathol. 2014 Apr;42(4):333-7. doi: 10.1002/dc.23096. Epub 2014 Feb 19.

11.

Molecular profiling for personalized cancer care.

Ashfaq R.

Clin Exp Metastasis. 2012 Oct;29(7):653-5. doi: 10.1007/s10585-012-9483-3. Epub 2012 Jun 8.

12.

Molecular profiling of individual tumor cells by hyperspectral microscopic imaging.

Uhr JW, Huebschman ML, Frenkel EP, Lane NL, Ashfaq R, Liu H, Rana DR, Cheng L, Lin AT, Hughes GA, Zhang XJ, Garner HR.

Transl Res. 2012 May;159(5):366-75. doi: 10.1016/j.trsl.2011.08.003. Epub 2011 Sep 3.

13.

Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers.

Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, Lotan Y.

J Urol. 2012 Feb;187(2):457-62. doi: 10.1016/j.juro.2011.10.031. Epub 2011 Dec 15.

PMID:
22177145
14.

Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.

Chromecki TF, Cha EK, Pummer K, Scherr DS, Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF.

BJU Int. 2012 Jul;110(1):63-8. doi: 10.1111/j.1464-410X.2011.10703.x. Epub 2011 Nov 11.

15.

Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.

Euhus D, Bu D, Xie XJ, Sarode V, Ashfaq R, Hunt K, Xia W, O'Shaughnessy J, Grant M, Arun B, Dooley W, Miller A, Flockhart D, Lewis C.

Cancer Prev Res (Phila). 2011 Nov;4(11):1852-62. doi: 10.1158/1940-6207.CAPR-11-0186. Epub 2011 Jul 21.

16.

Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.

Patschan O, Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Lotan Y, Hotakainen K, Stenman UH, Bjartell A.

World J Urol. 2012 Dec;30(6):785-94. doi: 10.1007/s00345-011-0727-7. Epub 2011 Jul 8.

PMID:
21739120
17.

Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study.

Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, van Rhijn BW, Bostrom P, Yao J, Miyamoto H, Jewett M, Fleshner N, Messing E, Zlotta AR.

BJU Int. 2011 Jul;108(1):24-30. doi: 10.1111/j.1464-410X.2010.09834.x. Epub 2010 Nov 10.

18.

Analysis of genetic copy number changes in cervical disease progression.

Policht FA, Song M, Sitailo S, O'Hare A, Ashfaq R, Muller CY, Morrison LE, King W, Sokolova IA.

BMC Cancer. 2010 Aug 16;10:432. doi: 10.1186/1471-2407-10-432.

19.

Microsatellite instability among individuals of Hispanic origin with colorectal cancer.

Gupta S, Ashfaq R, Kapur P, Afonso BB, Nguyen TP, Ansari F, Boland CR, Goel A, Rockey DC.

Cancer. 2010 Nov 1;116(21):4965-72. doi: 10.1002/cncr.25486.

20.

Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology.

Youssef RF, Schlomer BJ, Ho R, Sagalowsky AI, Ashfaq R, Lotan Y.

Urol Oncol. 2012 May-Jun;30(3):273-7. doi: 10.1016/j.urolonc.2010.02.012. Epub 2010 May 6.

PMID:
20451422
21.

Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers.

Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y.

J Urol. 2010 May;183(5):1744-50. doi: 10.1016/j.juro.2010.01.018. Epub 2010 Mar 17.

PMID:
20299037
22.

Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder.

Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, Lotan Y.

BJU Int. 2010 Oct;106(8):1216-22. doi: 10.1111/j.1464-410X.2009.09190.x.

23.
24.

Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.

Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ, Lotan Y.

J Urol. 2010 Jan;183(1):68-75. doi: 10.1016/j.juro.2009.08.115.

PMID:
19913255
25.

Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study.

Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y.

Clin Cancer Res. 2009 Nov 15;15(22):7012-9. doi: 10.1158/1078-0432.CCR-08-2554. Epub 2009 Nov 10. Erratum in: Clin Cancer Res. 2015 Jul 1;21(13):3096.

26.

Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature.

Bogusz AM, Seegmiller AC, Garcia R, Shang P, Ashfaq R, Chen W.

Am J Clin Pathol. 2009 Oct;132(4):597-605. doi: 10.1309/AJCPFUR1BK0UODTS. Review.

PMID:
19762538
27.

p53 expression in patients with advanced urothelial cancer of the urinary bladder.

Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Rigaud J, Müller SC, Lerner SP, Montorsi F, Sagalowsky AI, Cote RJ, Lotan Y.

BJU Int. 2010 Feb;105(4):489-95. doi: 10.1111/j.1464-410X.2009.08742.x. Epub 2009 Jul 31. Erratum in: BJU Int. 2015 Jun;115(6):E13.

28.

p53 predictive value for pT1-2 N0 disease at radical cystectomy.

Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Cote RJ.

J Urol. 2009 Sep;182(3):907-13. doi: 10.1016/j.juro.2009.05.024. Epub 2009 Jul 17.

PMID:
19616250
29.

Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder.

Bolenz C, Lotan Y, Ashfaq R, Shariat SF.

Eur Urol. 2009 Dec;56(6):1093-5. doi: 10.1016/j.eururo.2009.06.032. Epub 2009 Jul 7. No abstract available.

PMID:
19596509
30.

Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.

Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, Lotan Y.

J Urol. 2009 Jul;182(1):78-84; discussion 84. doi: 10.1016/j.juro.2009.02.125. Epub 2009 May 17. Erratum in: J Urol. 2015 May;193(5):1730.

PMID:
19447418
31.

Saline-infusion sonography endometrial sampling compared with endometrial biopsy in diagnosing endometrial pathology.

Moschos E, Ashfaq R, McIntire DD, Liriano B, Twickler DM.

Obstet Gynecol. 2009 Apr;113(4):881-7. doi: 10.1097/AOG.0b013e31819b3fc7.

PMID:
19305334
32.

Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.

Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Shariat SF.

J Natl Cancer Inst. 2009 Jan 21;101(2):114-9. doi: 10.1093/jnci/djn451. Epub 2009 Jan 13.

PMID:
19141773
33.

Cytologic diagnosis of blastocystis hominis in peritoneal fluid: a case report.

Patino WD, Cavuoti D, Banerjee SK, Swartz K, Ashfaq R, Gokaslan T.

Acta Cytol. 2008 Nov-Dec;52(6):718-20.

PMID:
19068678
34.

Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification.

Chen S, Auletta T, Dovirak O, Hutter C, Kuntz K, El-ftesi S, Kendall J, Han H, Von Hoff DD, Ashfaq R, Maitra A, Iacobuzio-Donahue CA, Hruban RH, Lucito R.

Cancer Biol Ther. 2008 Nov;7(11):1793-802. Epub 2008 Nov 21.

PMID:
18836286
35.

Differential expression of multiple genes in association with MADH4/DPC4/SMAD4 inactivation in pancreatic cancer.

Cao D, Ashfaq R, Goggins MG, Hruban RH, Kern SE, Iacobuzio-Donahue CA.

Int J Clin Exp Pathol. 2008 Apr 10;1(6):510-7.

36.

Differential roles of telomere attrition in type I and II endometrial carcinogenesis.

Akbay EA, Contreras CM, Perera SA, Sullivan JP, Broaddus RR, Schorge JO, Ashfaq R, Saboorian H, Wong KK, Castrillon DH.

Am J Pathol. 2008 Aug;173(2):536-44. doi: 10.2353/ajpath.2008.071179. Epub 2008 Jul 3.

37.

Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.

Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, Shariat SF.

Eur Urol. 2009 May;55(5):1124-33. doi: 10.1016/j.eururo.2008.06.054. Epub 2008 Jun 23.

PMID:
18585843
38.

False-positive sentinel lymph nodes in breast cancer patients caused by benign glandular inclusions: report of three cases and review of the literature.

Peng Y, Ashfaq R, Ewing G, Leitch AM, Molberg KH.

Am J Clin Pathol. 2008 Jul;130(1):21-7; quiz 146. doi: 10.1309/JVB8QFQNW5HBN7UJ. Review.

PMID:
18550466
39.

HMGA2 participates in transformation in human lung cancer.

Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R, Resar LM.

Mol Cancer Res. 2008 May;6(5):743-50. doi: 10.1158/1541-7786.MCR-07-0095.

40.

Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.

Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R.

J Urol. 2008 Jun;179(6):2164-9. doi: 10.1016/j.juro.2008.01.105. Epub 2008 Apr 18.

PMID:
18423745
41.

New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8.

Karanjawala ZE, Illei PB, Ashfaq R, Infante JR, Murphy K, Pandey A, Schulick R, Winter J, Sharma R, Maitra A, Goggins M, Hruban RH.

Am J Surg Pathol. 2008 Feb;32(2):188-96. doi: 10.1097/PAS.0b013e31815701f3.

42.
43.

Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.

Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, Sagalowsky AI, Lotan Y.

Cancer. 2008 Jan 15;112(2):315-25.

44.

Progesterone receptor expression is a marker for early stage breast cancer: implications for progesterone receptor as a therapeutic tool and target.

Coyle YM, Xie XJ, Hardy DB, Ashfaq R, Mendelson CR.

Cancer Lett. 2007 Dec 18;258(2):253-61. Epub 2007 Oct 22.

PMID:
17950525
45.

Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.

Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF.

Urology. 2007 Sep;70(3):482-6.

PMID:
17905101
46.

Simplifying the preevacuation testing strategy for patients with molar pregnancy.

Knowles LM, Drake RD, Ashfaq R, Castrillon DH, Miller DS, Schorge JO.

J Reprod Med. 2007 Aug;52(8):685-8.

PMID:
17879828
47.

Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk.

Euhus DM, Bu D, Ashfaq R, Xie XJ, Bian A, Leitch AM, Lewis CM.

Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1812-21.

48.

Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome.

Huang HY, Shariat SF, Sun TT, Lepor H, Shapiro E, Hsieh JT, Ashfaq R, Lotan Y, Wu XR.

Hum Pathol. 2007 Nov;38(11):1703-13. Epub 2007 Aug 17.

49.

Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.

Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4400-6.

50.

The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis.

Tesfaye A, Di Cello F, Hillion J, Ronnett BM, Elbahloul O, Ashfaq R, Dhara S, Prochownik E, Tworkoski K, Reeves R, Roden R, Ellenson LH, Huso DL, Resar LM.

Cancer Res. 2007 May 1;67(9):3998-4004.

Supplemental Content

Loading ...
Support Center